DNA Damage Repair Deficiency, Oxidative Stress, Sleep Quality
Conditions
Keywords
Melatonin, Sleep quality, DNA Damage, Lipid peroxidation, Nightshift worker
Brief summary
This research aims to determine if melatonin supplementation, through improvements in sleep quality, increases the ability to repair oxidative DNA damage and reduce lipid peroxidation levels among nightshift workers.
Detailed description
Administering a 3 mg melatonin supplement to nightshift workers prior to day sleep may significantly improve their oxidative DNA damage repair capacity and reduce the occurrence of lipid peroxidation \[measured as increased excretion of urinary 8-hydroxydeoxyguanosine (8-OH-dG) and decreased excretion of urinary 8-isoprostane, respectively\] through improvements in sleep quality (measured via actigraphy) and melatonin's direct antioxidative properties.
Interventions
DIETARY_SUPPLEMENTMelatonin
Participants will be randomized into two groups (Group A and Group B). Group A will initially be treated with 3 mg melatonin supplements over a 4-week period while Group B will initially receive placebo supplements over a 4-week period. After a 4-week washout period, Group A will receive placebo supplements while Group B will receive 3 mg melatonin supplements.
OTHERPlacebo
Placebo
Sponsors
University of British Columbia
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
Eligibility criteria included: 1) living and working in the Greater Vancouver area; 2) being between the ages of 18 and 50; 3) having a body mass index (BMI) between 18.5 and 30 kg/m2; 4) working at least two consecutive night shifts per week (≥7 hours per night ending no earlier than 06:00) for at least six months; 5) sleeping, on average, six hours during day sleep periods; 6) not currently using marijuana or illicit drugs; 7) no personal history of sleep disorders, hormone disorders, seizure disorders, or chronic medical conditions (e.g., cancer, diabetes, kidney disease, liver disease, asthma, cardiovascular disease, and infectious disease); 8) not currently pregnant or currently breast feeding; 9) no trans-meridian travel within fours weeks of data collection; and 10) not currently using melatonin supplements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Oxidative DNA damage repair capacity | During day sleep and during night work at baseline and one month | Measured as urinary concentration of 8-hydroxydeoxyguanosine (ng/mg-Creatinine) between baseline and one month as measured using liquid chromatography tandem mass spectrometry |
| Sleep duration | During day sleep at baseline and one month | Measured sleep duration (total minutes asleep) using wrist-based actigraphy device |
| Karolinska Sleepiness Scale | During night shift work at baseline and one month | Self-reported level of sleepiness on 9 point scale |
Countries
Canada
Outcome results
None listed